Lantus
Lantus is a long-acting, recombinant human insulin analog. It is designed to provide a steady, peakless level of insulin over a 24-hour period to mimic the basal insulin secretion of a healthy pancreas.
Dosage by Body Weight
Inject subcutaneously once daily at any time of day, but consistently at the same time each day. Dosage must be highly individualized based on metabolic needs, blood glucose monitoring results, and glycemic control goals under strict medical supervision.
- Body Weight
- Below 5 kg
- Dose
- Individualized by physician
- Frequency
- Once daily
- Tracking Notes
- Extremely sensitive population. Safety and effectiveness in pediatric patients with type 1 diabetes under 2 years of age have not been established.
- Body Weight
- 5-7 kg
- Dose
- Individualized by physician
- Frequency
- Once daily
- Tracking Notes
- Dose must be calculated meticulously (usually starting at 0.1 to 0.2 units/kg) and adjusted based on regular blood glucose monitoring.
- Body Weight
- 8-10 kg
- Dose
- Individualized by physician
- Frequency
- Once daily
- Tracking Notes
- Carefully monitor for hypoglycemia. Total daily insulin requirements may vary significantly.
- Body Weight
- 11-15 kg
- Dose
- Individualized by physician
- Frequency
- Once daily
- Tracking Notes
- Requires close blood glucose monitoring, especially during changes in physical activity, meal patterns, or co-administered medications.
- Body Weight
- 16-20 kg
- Dose
- Individualized by physician
- Frequency
- Once daily
- Tracking Notes
- Dosing should be adjusted based on glycemic targets and metabolic demands.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Individualized by physician | Once daily | Extremely sensitive population. Safety and effectiveness in pediatric patients with type 1 diabetes under 2 years of age have not been established. |
| 5-7 kg | Individualized by physician | Once daily | Dose must be calculated meticulously (usually starting at 0.1 to 0.2 units/kg) and adjusted based on regular blood glucose monitoring. |
| 8-10 kg | Individualized by physician | Once daily | Carefully monitor for hypoglycemia. Total daily insulin requirements may vary significantly. |
| 11-15 kg | Individualized by physician | Once daily | Requires close blood glucose monitoring, especially during changes in physical activity, meal patterns, or co-administered medications. |
| 16-20 kg | Individualized by physician | Once daily | Dosing should be adjusted based on glycemic targets and metabolic demands. |
Formulation
Injection solution (100 units/mL in 10 mL vial)Prefilled pen (SoloStar 100 units/mL in 3 mL pen)
Purpose
To improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus.
Generic Name
Insulin glargineScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.